Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Jun;7(6):563–567. doi: 10.1111/j.1365-2125.1979.tb04643.x

Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide.

L Jordö, G Johnsson, P Lundborg, B A Persson, C G Regärdh, O Rönn
PMCID: PMC1429665  PMID: 465277

Abstract

1. The plasma levels and the urinary excretion of hydrochlorothiazide (HCT) have been studied after administration of single doses of 12.5 and 25 mg of the drug in solution and in combination with 100 mg of the selective beta 1-adrenoreceptor antagonist metoprolol in a rapidly dissolving tablet. 2. Metoprolol did not significantly influence the bioavailability or the time-course of HCT. 3. HCT had no significant effect on the time-course or the plasma levels of metoprolol. The average half-life, 4.4 +/- 0.9 h, is about the same as previously observed for separate doses of this drug. 4. It seems unlikely that repeated doses of the combination product studied will lead to biopharmaceutic or pharmacokinetic interactions of clinical importance.

Full text

PDF
564

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beermann B., Groschinsky-Grind M., Lindstrom B. Bioavailability of two hydrochlorothiazide preparations. Eur J Clin Pharmacol. 1977 Mar 11;11(3):203–205. doi: 10.1007/BF00606411. [DOI] [PubMed] [Google Scholar]
  2. Beermann B., Groschinsky-Grind M., Rosén A. Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):531–537. doi: 10.1002/cpt1976195part1531. [DOI] [PubMed] [Google Scholar]
  3. Bengtsson C., Johnsson G., Regårdh C. G. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther. 1975 Apr;17(4):400–408. doi: 10.1002/cpt1975174400. [DOI] [PubMed] [Google Scholar]
  4. Castenfors J., Johnsson H., Orö L. Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients. Acta Med Scand. 1973 Mar;193(3):189–195. doi: 10.1111/j.0954-6820.1973.tb10560.x. [DOI] [PubMed] [Google Scholar]
  5. Chalmers J. P., Korner P. I., Tiller D. J., Bune A. J., Steiner J. D., West M. J., Wing L. M., Uther J. F. Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension. Med J Aust. 1976 May 1;1(18):650–653. [PubMed] [Google Scholar]
  6. Chalmers J., Tiller D., Horvath J., Bune A. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial. Lancet. 1976 Aug 14;2(7981):328–331. doi: 10.1016/s0140-6736(76)92589-7. [DOI] [PubMed] [Google Scholar]
  7. Ervik M. Quantitative determination of metoprolol in plasma and urine by gas chromatography. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):136–144. doi: 10.1111/j.1600-0773.1975.tb03330.x. [DOI] [PubMed] [Google Scholar]
  8. Gatley M. S. To be taken as directed. J R Coll Gen Pract. 1968 Jul;16(1):39–44. [PMC free article] [PubMed] [Google Scholar]
  9. Johnsson G., Regårdh C. G., Sölvell L. Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):31–44. doi: 10.1111/j.1600-0773.1975.tb03320.x. [DOI] [PubMed] [Google Scholar]
  10. Lancaster R., Goodwin T. J., Peart W. S. The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients. Br J Clin Pharmacol. 1976 Jun;3(3):453–460. doi: 10.1111/j.1365-2125.1976.tb00621.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Meyer M. C., Whyatt P. L. Hydrochlorothiazide. J Am Pharm Assoc. 1976 Jan;16(1):47–50. [PubMed] [Google Scholar]
  12. O'Brien E. T., MacKinnon J. Propranolol and polythiazide in treatment of hypertension. Br Heart J. 1972 Oct;34(10):1042–1044. doi: 10.1136/hrt.34.10.1042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Regårdh C. G., Borg K. O., Johansson R., Johnsson G., Palmer L. Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm. 1974 Aug;2(4):347–364. doi: 10.1007/BF01061407. [DOI] [PubMed] [Google Scholar]
  14. Regårdh C. G., Johnsson G., Jordö L., Sölvell L. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):45–58. doi: 10.1111/j.1600-0773.1975.tb03321.x. [DOI] [PubMed] [Google Scholar]
  15. Tannenbaum P. J., Rosen E., Flanagan T., Crosley A. P., Jr The influence of dosage form on the activity of a diuretic agent. Clin Pharmacol Ther. 1968 Sep-Oct;9(5):598–604. doi: 10.1002/cpt196895598. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES